Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-20 pm EDT 5-day change 1st Jan Change
105.2 USD -1.41% Intraday chart for Blueprint Medicines Corporation -1.11% +14.06%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
CStone Gets Green Light for Local Manufacturing of AYVAKIT in China MT
Transcript : Blueprint Medicines Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing MT
Blueprint Medicines Insider Sold Shares Worth $259,263, According to a Recent SEC Filing MT
Blueprint Medicines Insider Sold Shares Worth $4,136,328, According to a Recent SEC Filing MT
Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer MT
Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting CI
Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target MT
Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing MT
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating MT
Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97 MT
Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating MT
Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises MT
Transcript : Blueprint Medicines Corporation, Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M MT
Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 CI
Transcript : Blueprint Medicines Corporation - Special Call
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing MT
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing MT
Blueprint Medicines Says Ayvakit Data in Indolent Systemic Mastocytosis Show Long-Term Efficacy, Safety MT
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting CI
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO CI
Wedbush Adjusts Blueprint Medicines' PT to $110 From $97, Keeps Outperform Rating MT
Blueprint Medicines Q4 Loss Narrows, Revenue Rises; Shares Up MT
Chart Blueprint Medicines Corporation
More charts
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
105.2 USD
Average target price
119.4 USD
Spread / Average Target
+13.50%
Consensus
  1. Stock Market
  2. Equities
  3. BPMC Stock
  4. News Blueprint Medicines Corporation
  5. Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises